Abstract
High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have